Epizyme Inc. (NASDAQ:EPZM)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued on Sunday.
A number of other brokerages have also recently weighed in on EPZM. Zacks Investment Research cut shares of Epizyme from a “buy” rating to a “sell” rating in a report on Tuesday, July 12th. Leerink Swann reiterated an “outperform” rating on shares of Epizyme in a report on Friday, October 7th. Finally, Wedbush reiterated an “outperform” rating and set a $22.00 price target on shares of Epizyme in a report on Friday, November 4th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Epizyme has an average rating of “Buy” and an average price target of $23.11.
Epizyme (NASDAQ:EPZM) remained flat at $11.70 during midday trading on Friday. The company had a trading volume of 160,411 shares. The stock’s market cap is $678.73 billion. The stock’s 50-day moving average is $9.88 and its 200 day moving average is $9.77. Epizyme has a 52 week low of $7.02 and a 52 week high of $18.29.
Epizyme (NASDAQ:EPZM) last announced its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.60) by $0.18. The business had revenue of $6.60 million for the quarter. Epizyme had a negative net margin of 1,205.01% and a negative return on equity of 41.56%. On average, equities research analysts predict that Epizyme will post ($1.98) earnings per share for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Primecap Management Co. CA increased its position in shares of Epizyme by 24.3% in the first quarter. Primecap Management Co. CA now owns 6,518,627 shares of the biopharmaceutical company’s stock worth $79,006,000 after buying an additional 1,273,000 shares during the period. Franklin Resources Inc. bought a new position in shares of Epizyme during the first quarter worth $14,544,000. Jennison Associates LLC increased its position in shares of Epizyme by 252.4% in the fourth quarter. Jennison Associates LLC now owns 893,913 shares of the biopharmaceutical company’s stock worth $14,320,000 after buying an additional 640,245 shares during the period. CQS Cayman LP bought a new position in shares of Epizyme during the second quarter worth $6,502,000. Finally, Deerfield Management Co. bought a new position in shares of Epizyme during the second quarter worth $6,372,000. Institutional investors own 80.13% of the company’s stock.